Exam 2, deck 3 Flashcards
most common age groups for VTE
neonates and teenagers
most common precipitating factor in VTE
Central venous access device (CVAD)
Anticoagulation in symptomatic and asymptomatic deep vein thrombosis or pulmonary embolism
- The American Society of Hematology (ASH) guideline panel recommends using anticoagulationin pediatric patients with symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) (
- The ASH guideline panel suggests either using anticoagulation or no anticoagulation in pediatric patients with asymptomatic DVT or PE
Thrombolysis, thrombectomy, and inferior vena cava filters in VTE
- against using thrombolysis followed by anticoagulation; rather, anticoagulation alone should be used in pediatric patients with DVT, submassive PE
2.The ASH guideline panel suggests using thrombolysis followed by anticoagulation, rather than anticoagulation alone, in pediatric patients with PE with hemodynamic compromise
3.suggests against using thrombectomy followed by anticoagulation; rather, anticoagulation alone should be used in pediatric patients with symptomatic DVT or PE
- suggests against using inferior vena cava (IVC) filter; rather anticoagulation alone should be used in pediatric patients with symptomatic DVT or PE
Antithrombin replacement therapy in VTE
- The ASH guideline panel suggests against using antithrombin (AT)-replacement therapy in addition to standard anticoagulation; rather, standard anticoagulation alone should be used in pediatric patients with DVT/cerebral sino venous thrombosis (CSVT)/PE
- ASH guideline panel suggests using AT replacement therapy in addition to standard anticoagulation rather than standard anticoagulation alone in pediatric patients with DVT/CSVT/PE who have failed to respond clinically to standard anticoagulation treatment and in whom subsequent measurement of AT concentrations reveals low AT levels based on age-appropriate reference ranges
CVAD-related thrombosis
- suggests no removal, rather than removal, of a functioning CVAD in pediatric patients with symptomatic CVAD-related thrombosis who continue to require venous access
2, removal, rather than no removal, of a nonfunctioning or unneeded CVAD in pediatric patients with symptomatic CVAD-related thrombosis
- suggests delayed removal of a CVAD until after initiation of anticoagulation (days), rather than immediate removal in pediatric patients with symptomatic central venous line–related thrombosis who no longer require venous access or in whom the CVAD is nonfunctioning
- ASH guideline panel suggests either removal or no removal of a functioning CVAD in pediatric patients who have symptomatic CVAD-related thrombosis with worsening signs or symptoms, despite anticoagulation and who continue to require venous access
Use of Low-molecular-weight heparin vs vitamin K antagonists in DTE
The ASH guideline panel suggests using either low-molecular-weight heparin or vitamin K antagonists in pediatric patients with symptomatic DVT or PE (conditional recommendation based on very low certainty in the evidence of effects
what happens in DIC
hemostasis is out of control
leading to coagulation all over the place
leads to organ ischemia
This uses up platelets and clotting factors
Other parts of body start to bleed even with slight damage of walls.
They have too much and too little clotting
Fibrin degradation products in circulation interferes with clot formation making hemostasis even more difficult
DIC is also called
consumption coagulopathy
Lab findings in DIC
decreased platelets
decreased fibrinogen
prolonged PT/PTT
elevated D Dimer (fibrin degradation product)
Treatment DIC
support organs with
-Ventilator
-Hemodynamic
-Transfusions
all if needed
fever/neutropenia def by megan harvey
A single temp of 38.3C (101) or
2 episodes of 38 (100.4) and above within a 24 hr period
or
Temp of 39C (100.4) persistent for one hour taken axillary orally or by tympanic probe
ANC formula by meg harvey
WBC x (%segs +%bands)
ANC <1500 neutropenia
ANC <1000 moderate neutropenia
ANC <500 severe neutropenia
ANC <100-200 profound neutropenia
When is ANC typically at lowest
7-14 days from start of round of chemo
common infection culprits in febrile neutropenia
Gram + Bacteria - coag neg staph. Staph aureus, strepto viridans and midas
Gram - Bacteria, enterobacter, pseudomonas
Anaerobic Bacteria - Clostr dificille, propionbacterum acnes
Fungus
Viruses- hsv varicella zoster, ebv, cmv, ect
others - pjp
what studies do you avoid in febrile neutropenia
lumbar puncture
tap shunt or reservoir
Abx in febrile neutropenia
Monotherapy
-Cefepime 50mg/kg IV q 8
-Meropenem 20-40 mg/kg IV q8
-Zosyn 80-100 mg/kg IV q8
Dual therapy
-Ceftazidime 33-50mg/kg IV q 8 and
Tobramycin 7.5 mg/kg/day IV q8 or 7-9mg/kg IV Q24
(monitor trough levels weekly with aminoglycoside administration due to nephron and ototoxicity)
Anaerobes
-Clindamycin 40mg/kg IV q6 (aspiration pneumonia)
-Flagyl 7.5mg/kg IV q6
-give flagyl if concern for abd infection, typhlitis, perianal or mucosal skin breakdown
Add Vanc if
-AmL receiving high dose Cytarabine (Ara-C) with risk of S.viridans due to interruption of mucosal integrity and risk of sepsis
-hypotensive or have signs of shock
-Mucositis
-Prior h/o alpha hemolytic strep bacteremia
-Concern for catheter site infection or skin breakdown
-Colonized with resistant organisms only sensitive to vancomycin
-Cardiac vegitations
(At risk for tox, monitor trough levels with goal of 10-15 for bacteremia, 15-20 for meningitis)
(at risk for impaired renal function, monitor renal function, electrolytes and fluid balance daily)
Vanc trough level goal for bacteremia and meningitis
10-15 for bacteremia
15-20 for meningitis
when should you cover for fungal in fever neutropenia
fever persists for >1 week
When you have a fever neutropenia pt who you are going to cover for fungal, what to order first
fungal blood culture
serum galactomannan
consider ENT consult for eval of sinuses with flexible scope
CT of sinuses, chest and/or abdomen to evaluate for fungal nodes
antifungal agents in fever neutropenia
Echinocandins - covers most candida and at least fungistatic to Aspergillus. Empiric fungal agents of choice.
-Micafungin
-Caspofungin
-Anidulafungin
Triazoles - Fungicidal to Aspergillus. If clinically worsening
-Fluconazole
-Voriconazole
-Posaconazole
Amphotericin B
-Significant toxicity potential (nephrotoxic)
-Lipid formulation (Ambisome) has less side effects, but is more expensive
HSV and VZV require treatment with
IV acyclovir
Valacyclovir
Famciclovir
If hemoc has VZV how does effect treatment
cessation of chemotherapy administration
labs to monitor when give Acyclovir
nephrotoxic - monitor renal function and fluid intake closely